Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApoAML: Venetoclax + 6-mercaptopurine in Relapsed/Refractory AML
2024-510717-15-00Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and mercaptopurine in acute myeloid leukemia (AML), sponsored by Antwerp University Hospital. Primary endpoint: Clinical response (CR, CRi, CRp, MLFS, PR). Planned start Feb 2024; status: authorised.
02
Drugs
venetoclaxmercaptopurine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-510717-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510717-15-00.